<?xml version="1.0" encoding="UTF-8"?>
<p>To overcome the COVID-19 pandemic, the development of effective therapeutic agents and vaccines is crucial. However, as of August 3, 2020, there are few therapeutic agents that have been approved for the treatment of COVID-19, and there are no vaccines [
 <xref rid="B4" ref-type="bibr">4</xref>]. Remdesivir is the only antiviral agent that showed efficacy in a randomized controlled trial [
 <xref rid="B5" ref-type="bibr">5</xref>], and dexamethasone is another medication that showed efficacy in severe COVID-19 patients [
 <xref rid="B6" ref-type="bibr">6</xref>]. However, having these medications is not enough to overcome the COVID-19 pandemic. Given the lack of therapeutic options for COVID-19 and vaccines, historical interventions for emerging infectious diseases have remerged as options for disease control. Given its rapid acquisition, convalescent plasma therapy has been considered as an emergency intervention in several pandemics, including the Spanish flu, severe acute respiratory syndrome coronavirus (SARS-CoV-1), and West Nile virus, and more recently, Ebola virus [
 <xref rid="B7" ref-type="bibr">7</xref>
 <xref rid="B8" ref-type="bibr">8</xref>
 <xref rid="B9" ref-type="bibr">9</xref>].
</p>
